Studies recommending palivizumab restriction have serious deficiencies

Journal of Managed Care Pharmacy

Volumn 16, Issue 7, 2010, Pages 509-511

  Stewart, Dan L ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

COST CONTROL; DRUG USE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; LETTER; PATIENT COMPLIANCE; PRACTICE GUIDELINE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; TREATMENT INDICATION; ECONOMICS; EPIDEMIOLOGY; METHODOLOGY; REIMBURSEMENT; RESEARCH; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SELECTION BIAS; STANDARDS; STATISTICS AND NUMERICAL DATA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; CONFOUNDING FACTORS (EPIDEMIOLOGY); COST SAVINGS; HOSPITALIZATION; HUMANS; REIMBURSEMENT MECHANISMS; RESEARCH; RESEARCH DESIGN; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; SELECTION BIAS;

EID: 77958530071     PISSN: 10834087     EISSN: None     Source Type: Journal    
DOI: 10.18553/jmcp.2010.16.7.509     Document Type: Letter

References (13)

1. Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD. Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization. J Manag Care Pharm. 2010;16(1):15-22. Available at: http://www.amcp.org/data/jmcp/ 15-22.pdf.
2. Diehl JL, Daw JR, Coley KC, Rayburg R. Medical utilization associated with palivizumab compliance in a commercial and managed Medicaid health plan. J Manag Care Pharm. 2010;16(1):23-31. Available at: http://www.amcp.org/data/jmcp/ 23-31.pdf.
3. Curtiss FR, Fairman KA. Utilization management opportunities for palivizumab for prophylaxis of respiratory syncytial virus complications in infants. J Manag Care Pharm. 2010;16(1):59-66. Available at: http://www.amcp.org/data/jmcp/59-66.pdf.
4. Signorello LB, McLaughlin JK, Lipworth L, Friis S, Sørensen HT, Blot WJ. Confounding by indication in epidemiologic studies of commonly used analgesics. Am J Ther. 2002;9(3):199-205.
5. Hall CB. Respiratory syncytial virus. In: Feigin RD, Cherry JD, eds. Textbook of Pediatric Infectious Diseases, Fourth edition. Philadelphia, PA: WB Saunders; 1998, 2087.
6. American Academy of Pediatrics Subcommittee on Diagnosis and Management of Bronchiolitis. Diagnosis and management of bronchiolitis. Pediatrics. 2006;118(4):1774-93. Available at: http://pediatrics.aappublications.org/cgi/ reprint/118/4/1774. Accessed July 29, 2010.
7. Synagis (palivizumab) package insert. Revised July 2010. Medimmune. Available at: http://www.medimmune.com/pdf/products/synagis-pi.pdf. Accessed July 28, 2010.
8. Stewart DL, Romero JR, Buysman EK, Fernandes AW, Mahadevia PJ. Total healthcare costs in the US for preterm infants with respiratory syncytial virus lower respiratory infection in the first year of life requiring medical attention. Curr Med Res Opin. 2009;(25):11:2795-804.
9. Speer M, Boron M, McLaruin K, et al. Delayed prophylaxis in children at high risk for severe RSV disease. Poster presented at: Meeting of Society for Pediatric Research; May 2005; San Diego, CA.
10. Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm. 2010;16(1):46-58. Available at: http://www.amcp.org/data/ jmcp/46-58.pdf.
11. American Academy of Pediatrics, Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics. 2009;124(6):1694-701. Available at: http://pediatrics. aappublications.org/cgi/reprint/124/6/1694. Accessed July 28, 2010
12. Krilov LR, Weiner LB, Yogev R, et al. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine. Pediatrics. 2009;124(6):1682-84.
13. Meissner HC, Bocchini JA Jr, Brady MT, Hall CB, Kimberlin DW, Pickering LK. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus. Pediatrics. 2009;124(6):1676-79.